Document is current
Any future updates will be listed below
-
Authors
Lee, Chang Seok
Jung, Sung Yun https://orcid.org/0000-0003-1521-7977
Yee, Rachel Sue Zhen https://orcid.org/0000-0001-6737-1947
Agha, Nadia H. https://orcid.org/0000-0001-5011-766X
Hong, Jin
Chang, Ting
Babcock, Lyle W.
Fleischman, Jorie D.
Clayton, Benjamin
Hanna, Amy D.
Ward, Christopher S. https://orcid.org/0000-0002-3445-6327
Lanza, Denise https://orcid.org/0000-0001-8750-6933
Hurley, Ayrea E.
Zhang, Pumin https://orcid.org/0000-0003-4063-3008
Wehrens, Xander H. T.
Lagor, William R. https://orcid.org/0000-0002-1703-5125
Rodney, George G. https://orcid.org/0000-0002-6968-1516
Hamilton, Susan L. https://orcid.org/0000-0003-0241-9369
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR072475)
- License Information
-
More Information
Article History
Received: 3 April 2023
Accepted: 7 September 2023
First Online: 14 September 2023
Competing interests
: The authors declare the following competing interests: X.H.T.W. is a founding partner and board member of Elex Biotech, a start-up company that developed drug molecules to target ryanodine receptors to treat cardiac arrhythmias. The remaining authors declare no competing interests.
